重组人脑利钠肽治疗心力衰竭

[1] Effects of intravenous ne-siritide on humancoronary vasomotor regulationand myocardial oxygen uptake. Michaels AD,Klein A,MaddenJA,et al. Circulation . 2003

[2] Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting(fromthe FUSION1Trial). Yancy CW,Saltzberg MT,Berkowitz RL,et al. The American Journal of Cardiology . 2004

[3] Sustained hemodenamic effects of aninfusion of nesiritide(human B-type natriuretic peptide)in heart failure Arandomized,double-blind,placebo-controlledclinical trial.Natrecor Study Group. Mills RM,LeJemtel TH,Horton DP,et al. .J AmColl Cardiol . 1999

[4] Effect of nesiritide(B-type natriuretic peptide)and dobutamine on ventricular arrhythmiasin the treatment of patients with acutely decompensated congestive heart failure:The PRECEDENTStudy. Burger AJ,Horton DP,LeJemtel T,et al. American Heart Journal . 2002

[5] Nesiritide for sec-ondary pul monary hypertension in patients with end-stage heart failure. O‘Dell KM,Kalus JS,Kucukarslan S,et al. AmJ Health Syst Pharm . 2005

[6] Nesiritide:new hope for acute heart failure syn-dromes. Burnett JC. EHJ . 2005

[7] Brain natri-uretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activationin experi mental heart failure. Cataliotti A,Boerrigter G,Costello-Boerrigter LC,et al. Circulation . 2004

[8] Intravenous ne-siritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial. Publication Committee for the VMAC Investigators. .JAMA . 2002

[9] Intravenous nesiritide,a natriuretic peptide,inthetreatment of decompensatedcongestive heart failure. Colucci WS,Elkayam U,Horton DP,et al. The New England Journal of Medicine . 2000

[10] Intravenous nesiritide(human B-type natri-uretic peptide)reduces plasma endothelin-1levelsin patients with de-compensated congestive heart failure. Aronson D,Burger AJ. The American Journal of Cardiology . 2002

[1] Effects of intravenous ne-siritide on humancoronary vasomotor regulationand myocardial oxygen uptake. Michaels AD,Klein A,MaddenJA,et al. Circulation . 2003

[2] Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting(fromthe FUSION1Trial). Yancy CW,Saltzberg MT,Berkowitz RL,et al. The American Journal of Cardiology . 2004

[3] Sustained hemodenamic effects of aninfusion of nesiritide(human B-type natriuretic peptide)in heart failure Arandomized,double-blind,placebo-controlledclinical trial.Natrecor Study Group. Mills RM,LeJemtel TH,Horton DP,et al. .J AmColl Cardiol . 1999

[4] Effect of nesiritide(B-type natriuretic peptide)and dobutamine on ventricular arrhythmiasin the treatment of patients with acutely decompensated congestive heart failure:The PRECEDENTStudy. Burger AJ,Horton DP,LeJemtel T,et al. American Heart Journal . 2002

[5] Nesiritide for sec-ondary pul monary hypertension in patients with end-stage heart failure. O‘Dell KM,Kalus JS,Kucukarslan S,et al. AmJ Health Syst Pharm . 2005

[6] Nesiritide:new hope for acute heart failure syn-dromes. Burnett JC. EHJ . 2005

[7] Brain natri-uretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activationin experi mental heart failure. Cataliotti A,Boerrigter G,Costello-Boerrigter LC,et al. Circulation . 2004

[8] Intravenous ne-siritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial. Publication Committee for the VMAC Investigators. .JAMA . 2002

[9] Intravenous nesiritide,a natriuretic peptide,inthetreatment of decompensatedcongestive heart failure. Colucci WS,Elkayam U,Horton DP,et al. The New England Journal of Medicine . 2000

[10] Intravenous nesiritide(human B-type natri-uretic peptide)reduces plasma endothelin-1levelsin patients with de-compensated congestive heart failure. Aronson D,Burger AJ. The American Journal of Cardiology . 2002